Rohit Aggarwal1, Chester V Oddis2, Danielle Goudeau2, Diane Koontz2, Zengbiao Qi2, Ann M Reed3, Dana P Ascherman4, Marc C Levesque2. 1. Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, docrota@gmail.com. 2. Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA. 3. Department of Pediatrics, Duke University School of Medicine, Durham, NC and. 4. Division of Rheumatology and Immunology, University of Miami Department of Medicine, Miami, FL, USA.
Abstract
OBJECTIVES: To determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs). METHODS:Treatment-resistant adult and pediatric myositis subjects (n = 200) receivedrituximab in the 44-week Rituximab in Myositis Trial. CSMs [muscle enzymes, manual muscle testing (MMT), physician and patient global disease activity, HAQ, and extramuscular disease activity] were evaluated monthly and anti-Jo-1 (n = 28), -TIF1-γ (n = 23), -SRP (n = 25) and -Mi-2 (n = 26) serum levels were measured using validated quantitative ELISAs. Temporal trends and the longitudinal relationship between myositis-associated autoantibodies levels and CSM were estimated using linear mixed models. RESULTS: Following rituximab, anti-Jo-1 levels decreased over time (P < 0.001) and strongly correlated with all CSMs (P < 0.008). Anti-TIF1-γ levels also decreased over time (P < 0.001) and were only associated with HAQ, MMT and physician and patient global disease activity. Anti-SRP levels did not change significantly over time, but were significantly associated with serum muscle enzymes. Anti-Mi-2 levels significantly decreased over time and were associated with muscle enzymes, MMT and the physician global score. CONCLUSION: Anti-Jo-1, anti-TIF1-γ and anti-Mi-2 levels in myositis subjects decreased after B cell depletion and were correlated with changes in disease activity, whereas anti-SRP levels were only associated with longitudinal muscle enzyme levels. The strong association of anti-Jo-1 levels with clinical outcomes suggests that anti-Jo-1 autoantibodies may be a good biomarker for disease activity.
RCT Entities:
OBJECTIVES: To determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs). METHODS: Treatment-resistant adult and pediatric myositis subjects (n = 200) received rituximab in the 44-week Rituximab in Myositis Trial. CSMs [muscle enzymes, manual muscle testing (MMT), physician and patient global disease activity, HAQ, and extramuscular disease activity] were evaluated monthly and anti-Jo-1 (n = 28), -TIF1-γ (n = 23), -SRP (n = 25) and -Mi-2 (n = 26) serum levels were measured using validated quantitative ELISAs. Temporal trends and the longitudinal relationship between myositis-associated autoantibodies levels and CSM were estimated using linear mixed models. RESULTS: Following rituximab, anti-Jo-1 levels decreased over time (P < 0.001) and strongly correlated with all CSMs (P < 0.008). Anti-TIF1-γ levels also decreased over time (P < 0.001) and were only associated with HAQ, MMT and physician and patient global disease activity. Anti-SRP levels did not change significantly over time, but were significantly associated with serum muscle enzymes. Anti-Mi-2 levels significantly decreased over time and were associated with muscle enzymes, MMT and the physician global score. CONCLUSION: Anti-Jo-1, anti-TIF1-γ and anti-Mi-2 levels in myositis subjects decreased after B cell depletion and were correlated with changes in disease activity, whereas anti-SRP levels were only associated with longitudinal muscle enzyme levels. The strong association of anti-Jo-1 levels with clinical outcomes suggests that anti-Jo-1 autoantibodies may be a good biomarker for disease activity.
Authors: F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg Journal: Rheumatology (Oxford) Date: 2001-11 Impact factor: 7.580
Authors: Kerry B Stone; Chester V Oddis; Noreen Fertig; Yasuhiro Katsumata; Mary Lucas; Molly Vogt; Robyn Domsic; Dana P Ascherman Journal: Arthritis Rheum Date: 2007-09
Authors: Stephanie O Keeling; Robert Landewe; Desiree van der Heijde; Joan Bathon; Maarten Boers; Patrick Garnero; Piet Geusens; Hani El-Gabalawy; Robert D Inman; Virginia B Kraus; Tore K Kvien; Philip J Mease; Mikkel Ostergaard; Chris Ritchlin; Silje W Syversen; Walter P Maksymowych Journal: J Rheumatol Date: 2007-03 Impact factor: 4.666
Authors: O M Zack Howard; Hui Fang Dong; De Yang; Nina Raben; Kanneboyina Nagaraju; Antony Rosen; Livia Casciola-Rosen; Michael Härtlein; Michael Kron; David Yang; Kwabena Yiadom; Sunita Dwivedi; Paul H Plotz; Joost J Oppenheim Journal: J Exp Med Date: 2002-09-16 Impact factor: 14.307
Authors: Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto Journal: Nat Rev Rheumatol Date: 2018-04-12 Impact factor: 20.543
Authors: Iago Pinal-Fernandez; Christopher A Mecoli; Maria Casal-Dominguez; Katherine Pak; Yuji Hosono; Julio Huapaya; Wilson Huang; Jemima Albayda; Eleni Tiniakou; Julie J Paik; Cheilonda Johnson; Sonye K Danoff; Andrea M Corse; Lisa Christopher-Stine; Andrew L Mammen Journal: Neurology Date: 2019-10-08 Impact factor: 9.910
Authors: Christopher A Mecoli; Jemima Albayda; Eleni Tiniakou; Julie J Paik; Umar Zahid; Sonye K Danoff; Livia Casciola-Rosen; Maria Casal-Dominguez; Katherine Pak; Iago Pinal-Fernandez; Andrew L Mammen; Lisa Christopher-Stine Journal: Arthritis Rheumatol Date: 2020-01 Impact factor: 10.995
Authors: Corinna Preuße; Barbara Paesler; Christopher Nelke; Derya Cengiz; Thomas Müntefering; Andreas Roos; Damien Amelin; Yves Allenbach; Akinori Uruha; Carsten Dittmayer; Andreas Hentschel; Marc Pawlitzki; Sarah Hoffmann; Sara Timm; Sarah Leonard Louis; Nora F Dengler; Heinz Wiendl; Jan D Lünemann; Albert Sickmann; Baptiste Hervier; Sven G Meuth; Udo Schneider; Anne Schänzer; Sabine Krause; Stylianos Tomaras; Eugen Feist; Rebecca Hasseli; Hans-Hilmar Goebel; Laure Gallay; Nathalie Streichenberger; Olivier Benveniste; Werner Stenzel; Tobias Ruck Journal: Acta Neuropathol Date: 2022-05-25 Impact factor: 15.887
Authors: Ho So; Victor Tak Lung Wong; Virginia Weng Nga Lao; Hin Ting Pang; Ronald Man Lung Yip Journal: Clin Rheumatol Date: 2018-04-30 Impact factor: 2.980
Authors: Bryan A Joosse; James H Jackson; Alberto Cisneros; Austin B Santhin; Scott A Smith; Daniel J Moore; Leslie J Crofford; Erin M Wilfong; Rachel H Bonami Journal: Front Immunol Date: 2021-05-24 Impact factor: 8.786